Table 2.
Multivariable Cox regression model for prostate cancer incidence.
|
Incident prostate cancer. (218 clinically confirmed cases during the ASPREE trial, excluding all prevalent cases) | ||||||
| Variable |
PRS as Continuous Variable
(per Standard Deviation) |
PRS as Categorical Variable
(low, medium, high) |
||||
| Hazard Ratio | 95% CI | p-Value | Hazard Ratio | 95% CI | p-Value | |
| PRS (per std dev) | 1.52 | (1.33; 1.74) | <0.0001 | |||
|
Low PRS 0–20% (n = 23) |
Reference | |||||
|
Medium PRS >20–80% (n = 128) |
1.74 | (1.14; 2.66) | 0.01 | |||
|
High PRS >80% (n = 57) |
2.99 | (1.90; 4.72) | <0.0001 | |||
Cox proportional hazards model, adjusted for first-degree family history of prostate cancer, age at enrolment, and trial arm (aspirin/placebo).